Back to search

Article

Racial Disparities in Neutrophil Counts Among Patients with Metastatic Breast Cancer during Treatment with CDK4/6 Inhibitors

2022-01-03

Abstract excerpt

<title>Abstract</title> <p><bold>Purpose: </bold>The three CDK4/6 inhibitors (CDK4/6i) approved for use in HR-positive/HER2-negative metastatic breast cancer (MBC), palbociclib, ribociclib, and abemaciclib, are generally well tolerated but their most common toxicity is neutropenia. Within the general population, neutropenia has been shown to be more common in individuals of African descent. The landmark CDK4/6i t...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
a3db10cc-23ab-5b15-9287-6ea3c7c3cb6f
DOI
10.21203/rs.3.rs-1186162/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Racial Disparities in Neutrophil Counts Among Patients with Metastatic Breast Cancer during Treatment with CDK4/6 InhibitorsDOI 10.21203/rs.3.rs-1186162/v1
Differences in metabolic transport and resistance mechanisms of Abemaciclib, Palbociclib, and RibociclibSemantic proximity
Pre-existing effector T-cell levels and augmented myeloid cell composition denote response to CDK4/6 inhibitor palbociclib and pembrolizumab in hormone receptor-positive metastatic breast cancer.Semantic proximity
Adverse Event Profiles of CDK4/6 inhibitors: A pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) databaseSemantic proximity
Infectious Complications of Cyclin-Dependent Kinases 4 and 6 Inhibitors in Patients With Hormone Receptor-Positive Metastatic Breast Cancer: A Systematic Review and Meta-analysisSemantic proximity
Polyclonal RB1 mutations and acquired resistance to CDK 4/6 inhibitors in patients with metastatic breast cancer.Semantic proximity
NLR Dynamics During CDK4/6 Inhibition Predict Overall Survival in Metastatic Breast CancerSemantic proximity
CDK4/6 Inhibitors in Breast Cancer Treatment: Potential Interactions with Drug, Gene, and Pathophysiological ConditionsSemantic proximity
Tolerability of Eribulin and Correlation Between Polymorphisms and Neuropathy in an Unselected Population of Female Patients with Metastatic Breast Cancer: Results of The Multicenter, Single Arm, Phase IV PAINTER StudySemantic proximity
ABCG2 genetic polymorphism as risk factor for neutropenia in patients with metastatic or advanced hormone receptor -positive, HER2-negative breast cancer treated with palbociclibSemantic proximity
Evaluation of the Association of Polymorphisms With Palbociclib-Induced Neutropenia: Pharmacogenetic Analysis of PALOMA-2/-3Semantic proximity
ABCG2 genetic variant as risk factor for neutropenia in patients with metastatic or advanced hormone receptor -positive, HER2-negative breast cancer treated with palbociclibSemantic proximity
ABCG2 genetic variant as a predictor of severe neutropenia in Japanese patients with hormone receptor–positive, HER2-negative advanced breast cancer treated with palbociclib: an exploratory real-world studySemantic proximity
Select a neighboring publication to make it the new centre.